26/04 2006 WED 16:55 FAX ++41 61 319 96 19 Pentapharm AG

図002/003 S.2 ととないでは100つ

25 Apr 06 17:24 25/04 2006 15:24 FAX +49 89 45563 899



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

1:11/691,528

Applicant

: Otaf Wilhelm : October 24, 2003

Filed TC/A.U.

; 1617

Examiner

: Abigail Manda Cotton

Docket No. : 2923-576 Customer No. : 6449 Confirmation No. : 7396

DECLARATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Mr. Olivier Kapp

_, deciare as follows:

- 1. The Pefabloc® Series was sold in 1997 and 1998 only for use in research, analytical applications and purification processes as indicated on page 17 of the Pentapharm 1997 catalog and page 18 of the Pentapharm 1998 catalog.
- 2. In 1997 and 1998 the Petabloc® Series was not advertised, sold as nor intended to be sold as a pharmaceutical active ingredient.
- 3. The undersigned further declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful

BEST AVAILABLE COPY

XX

26/04 2008 WED 16:55 FAX ++41 61 319 96 19 Pentapharm AG
25/04 2006 15:24 FAX +48 88 45563 889 PA WEICKWANN AFAX

Ø 003/003 ₩ 505/505

Serial No. 10/660,785 Page 2

talse statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

by

Name

Olivier Kapp

April 26, 2006

Date

Title

Manager Legal Department

Company

Pentapharm Ltd., Basel, Switzerland